{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-177157","form_type":"8-K12B","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.141232+00:00","generated_at":"2026-05-15T04:14:03.979585+00:00","sec_items":["1.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Senti Biosciences completes holding company reorganization; shares convert 1:1 to new parent SNTI","bullets":["Senti Biosciences Holdings becomes new public parent; each share of old common stock converted 1:1 into new common stock.","Stock continues trading on Nasdaq under same ticker SNTI; new CUSIP 816944 102.","No change in executive officers or board of directors; same management team remains in place.","Reorganization is tax-free for shareholders; no vote required under DGCL Section 251(g).","Business, assets, and operations of the combined entity are unchanged from pre-reorganization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-177157","json":"https://secwatch.observer/filing/0001193125-26-177157.json","markdown":"https://secwatch.observer/filing/0001193125-26-177157.md","text":"https://secwatch.observer/filing/0001193125-26-177157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/d279931d8k12b.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:14:03.979585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d06f0dbb4c2f38f0ac3b299058001bd9a15f4e4","claim":"Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Biosciences amended and restated its bylaws to simplify them after becoming a wholly-owned subsidiary (effective 2026-04-24).","evidence_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.4},{"claim_id":"280b1a9ee7a7c3931d1f6730542503b172187413","claim":"Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Holdings adopted an Amended and Restated Certificate of Incorporation, and Senti Biosciences adopted a Third Amended and Restated Charter to simplify its certificate of incorporation after becoming a wholly-owned subsidiary (effective 2026-04-24).","evidence_excerpt":"Upon consummation of the Reorganization, the Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings (the “Amended and Restated Certificate of Incorporation”) and the Amended and Restated Bylaws of Senti Biosciences Holdings (the “Amended and Restated Bylaws”) are the same as the second amended and restated certificate of incorporation and amended and restated bylaws of Senti Biosciences in effect immediately prior to consummation of the Reorganization, respectively, other than changes permitted by Section 251(g) of the DGCL.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.4},{"claim_id":"0d7194a187e7c8d95ac91d172d32d8f9db05e4f3","claim":"Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24).","evidence_excerpt":"Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.9},{"claim_id":"3a20df659cc2902b1fec40a99ce4601c0e9a7278","claim":"Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24).","evidence_excerpt":"on April 24, 2026, Senti Biosciences and Senti Biosciences Holdings entered into an Assignment and Assumption Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.9},{"claim_id":"440b8c8c97ff307545907270431e564cc5cbd50a","claim":"Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24).","evidence_excerpt":"On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.9},{"claim_id":"9794f1412bac12e1db829009d3a4dad8a5364233","claim":"Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24).","evidence_excerpt":"Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-214945","ticker":"MAN","company_name":"ManpowerGroup Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"ManpowerGroup declares $0.72 dividend; shareholders approve equity plan amendment and director removal without cause","event_type":"other_material","sec_items":["5.02","5.03","5.07","8.01","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: governance_change","same SEC item: 5.02, 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214945","json":"https://secwatch.observer/filing/0001193125-26-214945.json","markdown":"https://secwatch.observer/filing/0001193125-26-214945.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/0001193125-26-214945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/man-20260508.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"the Board of Directors of the Company amended Section 3.3 of Article III of the Company’s Amended and Restated By-Laws (the “ By-Laws Amendment ”) to permit the removal of a director with or without cause by the affirmative vote of two-thirds of the outstanding shares of capital stock of the Company entitled to vote at a meeting of shareholders duly called for such purpose. The effective date of the By-Laws Amendment is May 8, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/0001193125-26-214945-index.htm"}},{"accession":"0000790816-26-000019","ticker":null,"company_name":"BRANDYWINE OPERATING PARTNERSHIP, L.P.","filed_at":"2026-06-01T20:30:42+00:00","headline":"Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP","event_type":"other_material","sec_items":["1.01","2.03","5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000790816-26-000019","json":"https://secwatch.observer/filing/0000790816-26-000019.json","markdown":"https://secwatch.observer/filing/0000790816-26-000019.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/790816/000079081626000019/bdn-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"extended the maturity date of the Borrowers’ revolving credit facility","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm"}},{"accession":"0001193125-26-212007","ticker":"ENB","company_name":"ENBRIDGE INC","filed_at":"2026-05-07T23:59:59+00:00","headline":"Enbridge shareholders approve directors, auditor, say-on-pay, and rights plan at AGM","event_type":"other_material","sec_items":["1.01","3.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-212007","json":"https://secwatch.observer/filing/0001193125-26-212007.json","markdown":"https://secwatch.observer/filing/0001193125-26-212007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/895728/000119312526212007/0001193125-26-212007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/895728/000119312526212007/enb-20260506.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"the holders of common shares of Enbridge Inc. (the “Corporation”) voted to amend, reconfirm and approve the Corporation’s shareholder rights plan (the “Rights Plan”) under the terms of an agreement between the Corporation and Computershare Trust Company of Canada (“Computershare”), as rights agent.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/895728/000119312526212007/0001193125-26-212007-index.htm"}},{"accession":"0000001961-26-000006","ticker":null,"company_name":"WORLDS INC","filed_at":"2026-06-01T18:59:55+00:00","headline":"Worlds Inc. changes name to Gemaxel Inc., effective March 26, 2026","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000001961-26-000006","json":"https://secwatch.observer/filing/0000001961-26-000006.json","markdown":"https://secwatch.observer/filing/0000001961-26-000006.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/0000001961-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/wddd8k052826.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"On March 26, 2026 the Company amended ARTICLE FIRST of its Certificate of Incorporation and changed its name to Gemaxel Inc. from Worlds Inc.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/0000001961-26-000006-index.htm"}},{"accession":"0001539497-26-001624","ticker":null,"company_name":"BMO 2026-5C14 Mortgage Trust","filed_at":"2026-06-01T18:53:15+00:00","headline":"BMO 2026-5C14 transfers Compass Storage Whole Loan servicing to Benchmark 2026-V22","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-26-001624","json":"https://secwatch.observer/filing/0001539497-26-001624.json","markdown":"https://secwatch.observer/filing/0001539497-26-001624.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/0001539497-26-001624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/n5711_x18-8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"On March 25, 2026 (the “ Closing Date ”), BMO 2026-5C14 Mortgage Trust (the “ Issuing Entity ”) issued the BMO 2026-5C14 Mortgage Trust, Commercial Mortgage Pass-Through Certificates, Series 2026-5C14, pursuant to a Pooling and Servicing Agreement, dated as of March 1, 2026 (the “ Pooling and Servicing Agreement ”), between BMO Commercial Mortgage Securities LLC, as depositor, Midland Loan Services, a Division of PNC Bank, National Association, as master servicer, CWCapital Asset Management LLC, as special servicer, Pentalpha Surveillance LLC, as operating advisor and as asset representations reviewer, and Computershare Trust Company, National Association, as certificate administrator and as trustee.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/0001539497-26-001624-index.htm"}},{"accession":"0001493152-26-026548","ticker":"BTCS","company_name":"BTCS Inc.","filed_at":"2026-06-01T13:29:19+00:00","headline":"BTCS reduces stockholder quorum requirement from majority to 33.3%","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026548","json":"https://secwatch.observer/filing/0001493152-26-026548.json","markdown":"https://secwatch.observer/filing/0001493152-26-026548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/0001493152-26-026548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/form8-k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"On May 29, 2026, the board of directors of BTCS Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) and adopted an amendment to the quorum requirement contained in Article II, Section 2.9 of the Bylaws (the “Amendment”) to provide that the holders of thirty-three and one third percent (33.3%) of the voting power of the Company entitled to vote at a meeting of stockholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/0001493152-26-026548-index.htm"}},{"accession":"0001682852-26-000101","ticker":"MRNA","company_name":"Moderna, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000101","json":"https://secwatch.observer/filing/0001682852-26-000101.json","markdown":"https://secwatch.observer/filing/0001682852-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/mrna-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm"}},{"accession":"0001065696-26-000036","ticker":"LKQ","company_name":"LKQ CORP","filed_at":"2026-05-08T23:59:59+00:00","headline":"LKQ stockholders approve 25% special meeting right; all director nominees elected","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001065696-26-000036","json":"https://secwatch.observer/filing/0001065696-26-000036.json","markdown":"https://secwatch.observer/filing/0001065696-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/0001065696-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/lkq-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm","comparable_excerpt":"the Company’s stockholders, upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment (the “Charter Amendment”) to the Company’s Restated Certificate of Incorporation to provide stockholders holding a combined 25% or more of the Company’s common stock with the right to request a special meeting of stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/0001065696-26-000036-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}